BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

Ipsen, Vernalis deal

Vernalis received $1.9 million as the final milestone payment from Ipsen under a 2008 deal in which Ipsen acquired Vernalis' U.S. commercial operations subsidiary and U.S. rights to Vernalis' Apokyn apomorphine. The payment brings the...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >